Latest move to cut funding for vaccines is not down to US health secretary. It is part of Trump’s wider war on science.

Donald Trump’s plan to force down drug prices in the United States by demanding pharmaceutical companies raise prices in ...

The growing healthcare burden posed by hepatocellular carcinoma, the most common subtype of liver cancer, has prompted the ...

How could Trump's demands that drugmakers lower U.S. prices or face penalties impact pharma and biotech stocks? Seeking Alpha ...

So Sir Pascal may seem an unlikely ally of Donald Trump, who as America’s president has slashed public spending on scientific research and seems determined to scrap the research grants of Ivy League ...

AstraZeneca and Eccogene are advancing ECC5004, a once-daily GLP-1 receptor agonist pill. Early stage trial showed a ...

Health and Human Services Secretary Robert F. Kennedy Jr. is cancelling 22 mRNA vaccine contracts funded by BARDA. Without evidence, Kennedy claimed these vaccines fail to protect effectively against ...

Meanwhile, drugmakers ramp up U.S. manufacturing investments to navigate policy shifts and protect supply chain resilience.

Trump demands U.S. drug prices match lowest international rates for some or face executive action. This article originally ...

A federal appeals court opened the door Aug. 6 for an amended class-action lawsuit alleging that Astrazeneca plc, Eli Lilly ...